Spots Global Cancer Trial Database for biliary tract cancers
Every month we try and update this database with for biliary tract cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | NCT06065371 | Gastrointestina... | Capecitabine Sacituzumab gov... | 18 Years - | Henry Ford Health System | |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | NCT04683939 | Solid Tumor Gastric Cancer Gastroesophagea... Esophageal Aden... Pancreatic Canc... Biliary Tract C... Cholangiocarcin... Metastatic Canc... | BNT141 Nab-paclitaxel Gemcitabine | 18 Years - | BioNTech SE | |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | NCT06037980 | Biliary Tract C... Cholangiocarcin... | Gemcitabine Nab paclitaxel Cisplatin Curative Surger... Capecitabine | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence | NCT06037980 | Biliary Tract C... Cholangiocarcin... | Gemcitabine Nab paclitaxel Cisplatin Curative Surger... Capecitabine | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | NCT06065371 | Gastrointestina... | Capecitabine Sacituzumab gov... | 18 Years - | Henry Ford Health System | |
| A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) | NCT05924880 | Biliary Tract C... | durvalumab | 18 Years - | AstraZeneca | |
| Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | NCT03447470 | Cancer Solid Tumor | RXC004 Nivolumab | 18 Years - | Redx Pharma Plc | |
| Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | NCT03447470 | Cancer Solid Tumor | RXC004 Nivolumab | 18 Years - | Redx Pharma Plc | |
| A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC) | NCT05924880 | Biliary Tract C... | durvalumab | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
